Navigation Links
Anadys Pharmaceuticals Augments Management Team and Board of Directors
Date:1/6/2011

#160;

Dr. Appleman, who has been with Anadys since 2001 in positions of increasing responsibility, most recently as Senior Vice President, Research, played pivotal roles in the invention and characterization of the Company's drug development candidates ANA598 and ANA773.  Dr. Appleman will continue to be responsible for non-clinical aspects of both development programs.  Dr. Appleman was a faculty member at St. Jude Children's Research Hospital and subsequently held positions at Gensia, Inc. and Metabasis Therapeutics, Inc. prior to joining Anadys.  He received a Ph.D. in Biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

Dr. Freddo joined Anadys in 2006 as Chief Medical Officer to build out the Company's clinical and regulatory functions and was named Senior Vice President of Drug Development in 2008.  Under his leadership both ANA598 and ANA773 entered clinical development and advanced to their current status.   Dr. Freddo joined Anadys from Pfizer, Inc. where he was most recently Vice President, Clinical Site Head and Development Site Head, La Jolla, and led the team responsible for the registration of Sutent®.  Prior to Pfizer, Dr. Freddo held a number of drug development positions at Wyeth-Ayerst.  Dr. Freddo serves as a member of the Board of Directors for InfuSystems Holdings, Inc.  Dr. Freddo received his M.D. and completed his fellowship training at the University of North Carolina and served on the faculty of the UCSD Medical Center prior to joining industry.

Dr. Papadopoulos assumes the role of Chairman of the Board from Steven H. Holtzman, who has resigned from the Board of Directors in association with his recent appointment as Executive Vice President, Corporate Development at Biogen Idec Inc.  Dr. Papadopoulos, who is a co-founder of Anadys and has been a member of the Board since 2000, has more than 25 years experience
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
5. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
6. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
7. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
8. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
9. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
10. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... 4 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ... of cancer and,hepatitis C virus (HCV) infection, today announced ... results ended July 31, 2007 on September,10, 2007, and ... the,results at 11:30 a.m. EDT on the same day. ...
... Sept. 4 Osteotech, Inc.,(Nasdaq: OSTE ), ... repair,of the musculoskeletal system, announced today that Sam ... an overview,of the Company,s strategic direction and market ... Investor Conference. Mr. Owusu-Akyaw is,scheduled to present at ...
... global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle East (PABME) 27-29 ... ... Emirates, Sept. 4 The Middle East,market for pharmaceutical manufacturing and biotechnology, ... digits. The market,drivers are: -- Dubai is the commercial, scientific and ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results 2
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/6/2014)... Most cancer deaths occur because of metastasis, yet ... has been slow. , "It,s been particularly challenging ... Taran Gujral, research fellow in systems biology at ... aren,t detected until after they,ve already metastasized." , ... culprit that should help researchers better understand how ...
(Date:11/5/2014)... Janeiro, Brazil -Individuals show great diversity in their ability ... and females greatly differ in their perceptual evaluation of ... smell tests. , Sex differences in olfactory ... and may be connected to one,s perception of smell, ... Thus, women,s olfactory superiority has been suggested to be ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... recently developed mouse model of brain,tumors common in ... human condition and provides unique insight,into tumor development, ... School of Medicine in St. Louis.,After validating their ... blood vessels and immune system cells may be ...
... at the Marine Biological,Laboratory (MBL) has published ... that supports her hypothesis that, when combined, ... as BCE--can act synergistically to alter a ... have previously studied the effects,of these pollutants ...
... crystallized form of a molecular machine that can cut ... for treating diseases such as some forms of cancer ... University researchers froze one of these molecular machines, which ... at mid-point in its work cycle. When frozen, crystallized ...
Cached Biology News:Mouse brain tumors mimic those in human genetic disorder 2Mouse brain tumors mimic those in human genetic disorder 3Clam embryo study shows pollutant mixture adversely affects nerve cell development 2Clam embryo study shows pollutant mixture adversely affects nerve cell development 3Molecular machine may lead to new drugs to combat human diseases 2Molecular machine may lead to new drugs to combat human diseases 3